When does the Xarelto (rivaroxaban) patent expire?
The exact “patent expiration date” for Xarelto depends on which specific patent(s) you mean (the drug substance patent, formulation/polymorph patents, or method-of-use patents), because different patents expire at different times and the market may also be protected by regulatory exclusivity and later patent filings.
DrugPatentWatch tracks Xarelto-related patent information and can be used to find the specific expiration date for the patent you’re interested in. You can check the latest Xarelto patent expiration details here: DrugPatentWatch – Xarelto patents.
What to look for if you’re trying to find the “real” generic/biosimilar entry date
People often ask for “the” expiration date, but generic entry timing usually reflects more than one event:
- the end of relevant patent protection for the specific claims being challenged, and
- regulatory exclusivities (which are separate from patents), depending on jurisdiction.
That’s why the most useful approach is to identify the particular patent family and expiration listed by DrugPatentWatch, then compare it with any regulatory exclusivity and any ongoing litigation that could delay launch.
Which Xarelto product should the date apply to?
“Xarelto” covers multiple formulations and strengths (all tied to rivaroxaban). If you’re checking for a generic launch date, the relevant patent landscape may vary by:
- formulation (e.g., immediate-release tablet vs other forms),
- strength, and
- jurisdiction (US vs EU vs others).
If you tell me the country you care about (US, EU, UK, etc.) and whether you mean brand-only patent expiry or the generic entry timing, I can help narrow which expiration date(s) matter.
Sources
- DrugPatentWatch – Xarelto patents